EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ventyx Biosciences's enterprise value is $46.51 Mil.
Ventyx Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Ventyx Biosciences's EV-to-Revenue for today is .
The historical rank and industry rank for Ventyx Biosciences's EV-to-Revenue or its related term are showing as below:
VTYX's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.66 * Ranked among companies with meaningful EV-to-Revenue only.
The historical data trend for Ventyx Biosciences's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ventyx Biosciences's EV-to-Revenue
For the Biotechnology subindustry, Ventyx Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ventyx Biosciences's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ventyx Biosciences's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Ventyx Biosciences's EV-to-Revenue falls into.
Ventyx Biosciences's current Enterprise Value is $46.51 Mil.
Ventyx Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ventyx Biosciences's share price for today is $3.93.
Ventyx Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ventyx Biosciences EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Ventyx Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Ventyx Biosciences (Ventyx Biosciences) Business Description
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VTYX has been successfully added to your 